LMAT at a glance
LEMAITRE VASCULAR INC (LMAT, SEC CIK 1158895) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), LEMAITRE VASCULAR INC (LMAT) reported revenue of $249.6 million (up 13.5% from FY2024) and net income of $57.7 million. Diluted EPS was $2.52.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding LEMAITRE VASCULAR INC (LMAT) shares worth $971.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $249.6M
- +13.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $971.8M · +0 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: global medical devices and human tissue cryopreservation services focused on treating peripheral vascular, end-stage renal, and cardiovascular diseases
- New product emphasis: launch of PhasTIPP Powered Phlebectomy System in US (H1 2024) and marketing of Artegraft biologic graft in EU after April 2025 CE mark approval
- Strategic shift: increased focus on adjacent cardiac surgeon market and expanded direct sales force (160 reps as of 12/31/2025) covering 95% of net sales
- Notable metric: biologic product sales represent 53% of total revenues in 2025, up from 51% in 2023; sales force steady at 160 representatives globally
- Unique fact: FDA issued warning letter in August 2025 on North Brunswick facility following April audit; company addressed eight observations, pending reinspection
Risk Factors
- Regulatory risk: ASC 606 revenue recognition standard requires judgment in estimating sales returns, impacting reported revenue and allowances
- Macroeconomic threat: $9.1 million inventory purchase commitments expose business to supply cost fluctuations through 2026
- Operational vulnerability: inventory write-offs provisioning driven by product expiration and inaccurate future demand forecasts affect margins
- Market disruption risk: contingent consideration liabilities from acquisitions subject to performance criteria remeasured quarterly affect earnings volatility
- Financial risk: $167.8 million net proceeds from 2024 Convertible Notes issuance increase leverage and interest expense exposure
Management Discussion & Analysis
- Revenue $249.6M in 2025, up 14% YoY (+$29.7M from $219.9M in 2024) with highest growth in EMEA (+22%, +$13.2M)
- Gross margin 71.5% in 2025 vs 68.6% in 2024, up 290bps; driven by Employee Retention Credit, manufacturing efficiencies, and price increases
- Best segment EMEA net sales +$13.2M (22%); worst impact from product line wind-downs totaling ~$3M in 2025 revenues
- Cash and equivalents $28.2M (+$2.6M), short-term marketable securities $330.9M (+$56.8M); new $100M share repurchase authorized, no buys yet
- Management highlights growth via sales force expansion, acquisitions (e.g., Andramed for $1.8M), and new regulatory approvals; risks include product transitions and foreign exchange impacts
AI summary of the LMAT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- FDA re-inspection of Artegraft facility in June 2026 identified additional new observations
- Ongoing FDA warning-letter remediation requiring continued agency engagement and management resources
- Potential enforcement action or approval suspension threatening Artegraft operations and regulatory compliance
- April 2025 catheter packaging recall involving inadequate seals and potentially compromised sterile barriers
- Recall-related costs and customer replacements from TufTex, Pruitt Occlusion, and Pruitt Irrigation catheters
AI summary of the LMAT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q2 sales $70.4mm, up 10% organically, with organic growth reaching 12% excluding catheters
- Gross margin expanded 210 bps to 72.1%; operating income rose 26% to $20.4mm
Item 2.02: Results of Operations and Financial Condition
- Filing contains only forward-looking statement disclaimers, not reported financial results
- Investors should review the referenced earnings exhibit for fiscal-year 2026 performance and guidance
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholder turnout: 21.34M of 22.85M eligible shares represented, approximately 93.4% participation
- David B. Roberts and John A. Roush elected to three-year Class II director terms ending at the 2029 annual meeting
Item 2.02: Results of Operations and Financial Condition
- Filing contains only forward-looking-statement cautionary language
- Investors should rely on historical results and risk disclosures rather than projections in this excerpt
Item EX-99.1: Item EX-99.1
- Q1 sales $66.6M, up 11% with 10% organic growth, signaling broad-based demand acceleration
- Gross margin reached 72.7%, up 350 bps, while operating income rose 41% to $17.8M
AI summaries of LMAT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LMAT
Don't miss the next LMAT filing
- Alerts as it files. A push when LMAT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LMAT, by share count.
- Ask anything. An AI agent that reads every LMAT filing and answers with sources.
LMAT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Roush John A | A | Sep 3, 2026 | 0.885 | - |
| Roush John A | A | Sep 3, 2026 | 1.002 | - |
| Roush John A | A | Sep 3, 2026 | 1.664 | - |
| Jasinski Lawrence J | A | Sep 3, 2026 | 0.543 | - |
| Jasinski Lawrence J | A | Sep 3, 2026 | 0.65 | - |
| Jasinski Lawrence J | A | Sep 3, 2026 | 0.885 | - |
| Jasinski Lawrence J | A | Sep 3, 2026 | 1.002 | - |
| Jasinski Lawrence J | A | Sep 3, 2026 | 1.664 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $219.9M | $249.6M |
| Gross Profit | - | $150.9M | $178.5M |
| Operating Income | - | $52.3M | $67.9M |
| Net Income | $30.1M | $44.0M | $57.7M |
| Gross Margin | - | 68.6% | 71.5% |
| Op. Margin | - | 23.8% | 27.2% |
| Net Margin | - | 20.0% | 23.1% |
| Balance Sheet | |||
| Total Assets | - | $551.8M | $615.7M |
| Equity | $297.9M | $337.3M | $393.5M |
| ROE | 10.1% | 13.1% | 14.7% |
| Per Share | |||
| EPS | $1.34 | $1.93 | $2.52 |
| Cash Flow | |||
| Operating CF | $36.8M | $44.1M | $81.3M |
Source: XBRL data in LEMAITRE VASCULAR INC (LMAT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LMAT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $971.8M |
| Q1 2026 | 32 | $1.03B |
| Q4 2025 | 29 | $723.7M |
| Q3 2025 | 30 | $784.7M |
| Q2 2025 | 31 | $749.9M |
| Q1 2025 | 28 | $465.8M |
| Q4 2024 | 26 | $424.1M |
| Q3 2024 | 23 | $263.3M |
- T. Rowe Price Group+460.1K (+156%)
- BlackRock+128.8K (+4%)
- Invesco Ltd+114.4K (+34%)
- State Street Corp+45.6K (+5%)
- Vanguard Portfolio Management LLC+42.1K (+7%)
- Morgan Stanley−56.7K (-14%)
- Citadel Advisors LLC−54.3K (-56%)
- D.E. Shaw & Co−47.2K (-56%)
- Millennium Management−45.0K (-83%)
- JPMorgan Chase & Co−39.2K (-36%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 231 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LMAT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
LMAT SEC filings: frequently asked questions
Which institutions hold LMAT stock?
As of June 30, 2026, the largest LEMAITRE VASCULAR INC (LMAT) holders among the 13F filers tracked by SignalX were BlackRock ($314.1 million), Vanguard Capital Management LLC ($91.5 million), State Street Corp ($86.5 million), T. Rowe Price Group ($72.5 million), Vanguard Portfolio Management LLC ($58.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LMAT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), LEMAITRE VASCULAR INC (LMAT) reported revenue of $249.6 million (up 13.5% from FY2024) and net income of $57.7 million. Diluted EPS was $2.52. The figures come from the XBRL data in the 10-K.
What are the main risks in LMAT's latest 10-K?
In the 10-K filed February 26, 2026, LEMAITRE VASCULAR INC (LMAT) flagged: Regulatory risk: ASC 606 revenue recognition standard requires judgment in estimating sales returns, impacting reported revenue and allowances. Macroeconomic threat: $9.1 million inventory purchase commitments expose business to supply cost fluctuations through 2026. (AI summary of the Risk Factors section.)
What did LMAT report in its latest 8-K?
LEMAITRE VASCULAR INC (LMAT) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 sales $70.4mm, up 10% organically, with organic growth reaching 12% excluding catheters.
What are the latest LMAT SEC filings?
LEMAITRE VASCULAR INC (LMAT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 8, 2026.
What is LMAT's SEC CIK number?
LEMAITRE VASCULAR INC (LMAT)'s SEC Central Index Key (CIK) is 1158895. EDGAR lists every LMAT filing under that number.
Ask anything about LMAT
The research agent reads LMAT's filings, financials, insider trades and 13F holders, then answers with sources.